The analysis for CSF IgM binding to MO3.13 cells among MS subgroups and control showed a statistically significant difference in binding between control and RRMS, control and SPMS, CIS and SPMS, and RRMS and SPMS subgroups (Fig. 6D). The gene discussed is CD40LG; the disease is in situ carcinoma.